Dosage guide · 55 mg blend

Shred Stack Dosage Protocol

AOD-9604 + 5-Amino-1MQ · fixed-ratio research blend

Derived from the 5-Amino-1MQ component reference, the fixed-ratio blend works out to 2.75 mg total once daily for days 1–2, then 5.5 mg total once daily. With a 55 mg vial plus 2 mL, the concentration is 27.5 mg/mL, so 2.75 mg is 10 units (0.10 mL) on a U-100 syringe. This is not an established Shred Stack protocol.

How oftenOnce daily

Starting dose2.75 mg

Start = units10 units

Mix2 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Shred Stack 55 mg blend vial

Not currently stocked by Peak Peptides Australia

No product photo — this strength isn't stocked by Peak

Dosage chart How to mix Supplies Calculator About Shred Stack References

01 · DOSAGE CHART

Shred Stack dosage chart

Derived daily calculation · 55 mg blend + 2 mL BAC water

BAC water added

Concentration27.5 mg/mL totalUnequal blend — see split below

1 unit (U-100)275 mcg total= 0.01 mL

How oftenOnce dailySubcutaneous injection

2 mL is a calculation-only default: 55 mg ÷ 2 mL is 27.5 mg/mL, so 2.75 mg is 10 units; formulation compatibility is unverified.

Shred Stack dosage chart for a 55 mg blend vial mixed with 2 mL of bacteriostatic water
Days	Total blend dose	Syringe units	Syringe fill
Days 1–2Start	2.75 mg250 mcg AOD-9604 + 2.5 mg 5-Amino-1MQ	10 units0.1 mL
Day 3 onwards	5.5 mg500 mcg AOD-9604 + 5 mg 5-Amino-1MQ	20 units0.2 mL

Once daily · derived component calculation · subcutaneous injection

The 2.75 mg and 5.5 mg totals preserve the vial's 5 mg to 50 mg component ratio when the 5-Amino-1MQ reference amounts are used.

They contain 250 mcg then 500 mcg AOD-9604 alongside 2.5 mg then 5 mg 5-Amino-1MQ.

The separate AOD-9604 reference starts at 300 mcg, so no reconciled schedule exists for this fixed-ratio blend.

Derived component amounts only — no approved or clinically established human dose exists for this finished blend. Education only, not medical advice. Dose amounts adapted from 5-Amino-1MQ 50 mg vial dosage protocol, translated to the fixed 5 mg to 50 mg component ratio (PeptideDosages.com); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 55 mg blend vial with 2 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 2 full draws of bacteriostatic water gives 27.5 mg/mL in total.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 2 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 27.5 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 55 mg blend vial mixed with 2 mL.

Length of protocol

1Shred Stack 55 mg blend vial33 mg needed in total

81 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle2 mL used for mixing

16Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter the total blend amount; the split between peptides follows the blend ratio shown in the chart.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume2 mL

Amount to Evaluate (not a recommendation)

Concentration

27.50 mg/mL

(27500 mcg/mL)

Calculated Liquid Volume

0.100 mL

Equivalent U-100 volume scale position

10markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Shred Stack

Protocol overview

Starting amount: 2.75 mg total once daily for days 1–2
Thereafter: 5.5 mg total once daily from day 3
Component maths: 2.75 mg total = 250 mcg AOD-9604 + 2.5 mg 5-Amino-1MQ
Frequency: Once daily in the component reference
Common calculation mix: 2 mL gives 27.5 mg/mL; compatibility is unverified
Protocol status: Derived calculation only; no established blend schedule

Storage

Before mixing: Follow the exact blend label and supplier documentation; no product-specific sealed-vial condition was located.
After mixing: No validated prepared-solution stability duration was identified for this finished blend.
Never: Never use a reconstituted vial that is cloudy or has particles in it.

How it works

AOD-9604 is a synthetic 16-amino-acid growth-hormone fragment investigated for metabolic and obesity research. It is not full-length growth hormone.

5-Amino-1MQ is not a peptide: it is a small-molecule inhibitor of nicotinamide N-methyltransferase, an enzyme involved in nicotinamide metabolism. In cell and mouse research, NNMT inhibition has been studied for effects on adipose tissue and metabolic measures.

No human research establishes that combining these ingredients produces a synergistic effect, a compatible preparation or a predictable outcome.

Illustrated mechanism explainer

What the research shows

A 2013 obesity-pharmacotherapy review reported that a 12-week AOD-9604 study at 1 mg/day averaged 2.6 kg weight loss versus 0.8 kg with placebo; it also reported that a 24-week study of 536 people did not show significant weight loss and development ended.
In an 11-day diet-induced-obesity mouse experiment, 5-Amino-1MQ-treated mice lost 2.0 ± 0.6 g while controls gained 0.6 ± 0.4 g; each group had 9 mice. This was animal research, not a human dose study.
In a 28-day mouse experiment, high-dose 5-Amino-1MQ mice gained 0.9 g versus 5.4 g in controls; the figure reports 8 mice per group and no significant change in food intake. This does not establish a human outcome.
A rat pharmacokinetic report found mean terminal half-lives of 3.80 ± 1.10 hours after intravenous administration and 6.90 ± 1.20 hours after oral administration; rat exposure cannot define a human schedule.
No opened source provided a human clinical dose, safety assessment, compatibility assessment or efficacy result for the finished 55 mg AOD-9604 plus 5-Amino-1MQ blend.

Reported side effects

Human safety data for the finished blend have not been established, so adverse effects and interactions cannot be predicted from the component studies.
FDA identifies potential immunogenicity, peptide-related impurities and limited safety information as concerns for compounded AOD-9604, and says it lacks enough information to know whether it would cause harm in people.
The 5-Amino-1MQ efficacy findings above are from mice; an initial mouse dose-escalation reported no observable adverse effects at 60 mg/kg/day in 2 animals, which is not evidence of human safety.
The TGA warns that poorly labelled unapproved peptide products may have unverifiable contents, strength, sterility or contaminants.

Important notes

This research-labelled blend is not established as an approved medicine in the sources reviewed, and no clinically established human dose exists for the finished product.
Prohibited in sport: WADA lists AOD-9604 as a growth-hormone fragment prohibited at all times under S2.
A 5 mg to 50 mg fixed ratio cannot match both component starting schedules: the derived 250 mcg AOD-9604 start is below the separate 300 mcg AOD-9604 reference start.
No supplier document was provided to show that bacteriostatic water is compatible with both ingredients or to establish the mixed blend's stability.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

Shred Stack questions

How many U-100 units is the derived Shred Stack starting amount?

With the 55 mg blend mixed with 2 mL, the concentration is 27.5 mg/mL. The 2.75 mg derived starting amount is 10 units, or 0.10 mL, on a U-100 syringe; it contains 250 mcg AOD-9604 and 2.5 mg 5-Amino-1MQ.

How many U-100 units is the higher derived Shred Stack amount?

With the same 55 mg plus 2 mL calculation, 5.5 mg total is 20 units, or 0.20 mL. That fixed-ratio draw contains 500 mcg AOD-9604 and 5 mg 5-Amino-1MQ.

How long would a 55 mg Shred Stack vial last at the derived amounts?

A 55 mg vial contains 20 daily 2.75 mg draws or 10 daily 5.5 mg draws. If the two derived starter days are followed by 5.5 mg daily, the vial contains 11 days of material; this is supply maths, not a validated cycle.

Is there an established Shred Stack mixing or dosing protocol?

No. The reference site has no page for this exact 55 mg blend, and the separate component references do not fully agree at the starting amount. The 2 mL mix is shown only to make the derived concentration and U-100 conversion transparent; compatibility and stability of the finished blend were not established.

07 · SOURCES